EPS for Rigel Pharmaceuticals, Inc. (RIGL) Expected At $-0.13; Tensile Capital Management Lifted By $4.53 Million Its Transocean LTD (RIG) Stake

February 20, 2018 - By Hazel Jackson

Tensile Capital Management Llc increased Transocean Ltd (RIG) stake by 58.48% reported in 2017Q3 SEC filing. Tensile Capital Management Llc acquired 453,200 shares as Transocean Ltd (RIG)’s stock declined 20.06%. The Tensile Capital Management Llc holds 1.23 million shares with $13.22M value, up from 775,000 last quarter. Transocean Ltd now has $4.16 billion valuation. The stock decreased 1.52% or $0.14 during the last trading session, reaching $9.09. About 15.65M shares traded or 23.67% up from the average. Transocean Ltd. (NYSE:RIG) has risen 15.86% since February 20, 2017 and is uptrending. It has underperformed by 0.84% the S&P500.

Analysts expect Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report $-0.13 EPS on March, 6.They anticipate $0.03 EPS change or 18.75% from last quarter’s $-0.16 EPS. After having $-0.14 EPS previously, Rigel Pharmaceuticals, Inc.’s analysts see -7.14% EPS growth. The stock decreased 2.03% or $0.08 during the last trading session, reaching $3.87. About 666,693 shares traded. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 4.56% since February 20, 2017 and is uptrending. It has underperformed by 12.14% the S&P500.

Investors sentiment decreased to 0.95 in 2017 Q3. Its down 0.30, from 1.25 in 2017Q2. It fall, as 66 investors sold RIG shares while 107 reduced holdings. 54 funds opened positions while 110 raised stakes. 280.42 million shares or 7.79% more from 260.14 million shares in 2017Q2 were reported. Rocky Mountain Advisers Limited Liability Com reported 1,000 shares stake. Zweig has 0.31% invested in Transocean Ltd. (NYSE:RIG). Alliancebernstein Ltd Partnership holds 238,013 shares. Parkside Natl Bank Trust owns 159 shares for 0% of their portfolio. Pettee accumulated 34,499 shares. Ameritas Inv reported 116,800 shares or 0.05% of all its holdings. Ontario Teachers Pension Plan Board has invested 0.01% in Transocean Ltd. (NYSE:RIG). Qci Asset Mngmt New York invested 0% of its portfolio in Transocean Ltd. (NYSE:RIG). Systematic Lp reported 0.04% in Transocean Ltd. (NYSE:RIG). Benjamin F Edwards Communication Incorporated holds 10,186 shares or 0.01% of its portfolio. Sta Wealth Mgmt Limited Liability Corporation invested in 0.05% or 13,143 shares. Canada Pension Plan Board accumulated 1.80 million shares. San Francisco Sentry Inv Grp (Ca) reported 1,500 shares. Credit Suisse Ag holds 0.01% of its portfolio in Transocean Ltd. (NYSE:RIG) for 1.19 million shares. Counselors invested in 12,317 shares or 0.01% of the stock.

Among 40 analysts covering Transocean Ltd (NYSE:RIG), 15 have Buy rating, 10 Sell and 15 Hold. Therefore 38% are positive. Transocean Ltd had 105 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was upgraded by Goldman Sachs on Wednesday, August 9 to “Neutral”. Canaccord Genuity upgraded Transocean Ltd. (NYSE:RIG) on Thursday, November 3 to “Buy” rating. Cowen & Co maintained the shares of RIG in report on Wednesday, August 2 with “Hold” rating. BMO Capital Markets maintained the shares of RIG in report on Wednesday, April 19 with “Sell” rating. The stock of Transocean Ltd. (NYSE:RIG) has “Neutral” rating given on Wednesday, January 25 by Piper Jaffray. As per Tuesday, September 5, the company rating was maintained by Cowen & Co. As per Monday, May 16, the company rating was maintained by Citigroup. Howard Weil upgraded Transocean Ltd. (NYSE:RIG) rating on Tuesday, October 4. Howard Weil has “Sector Outperform” rating and $14 target. The stock of Transocean Ltd. (NYSE:RIG) earned “Buy” rating by R. F. Lafferty on Thursday, February 9. The stock of Transocean Ltd. (NYSE:RIG) has “Buy” rating given on Monday, December 19 by Evercore.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $566.92 million. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>